CYCN Cyclerion Therapeutics Inc
Price (delayed)
$2.61
Market cap
$7.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$3.84M
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates
Highlights
Cyclerion Therapeutics's EPS has increased by 46% YoY and by 43% from the previous quarter
The quick ratio has grown by 44% YoY and by 25% from the previous quarter
The equity has contracted by 22% YoY but it has grown by 8% from the previous quarter
Key stats
What are the main financial stats of CYCN
Market
Valuations
Earnings
Shares outstanding
2.71M
Market cap
$7.07M
Enterprise value
$3.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.8
Price to sales (P/S)
3.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.92
Revenue
$2M
Gross profit
$2M
Operating income
-$3.63M
Net income
-$3.06M
EBIT
-$3.06M
EBITDA
-$3.06M
Free cash flow
-$4.33M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
-$1.72
Book value per share
$3.27
Revenue per share
$0.79
TBVPS
$3.8
Total assets
$9.58M
Total liabilities
$725,000
Debt
$0
Equity
$8.85M
Working capital
$3.5M
Debt to equity
0
Current ratio
5.83
Quick ratio
5.22
Net debt/EBITDA
1.06
Margins
Efficiency
Dividend
EBITDA margin
-152.9%
Gross margin
100%
Net margin
-152.9%
Operating margin
-181.4%
Return on assets
-30.6%
Return on equity
-34.2%
Return on invested capital
-63.1%
Return on capital employed
-34.5%
Return on sales
-152.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYCN stock price
How has the Cyclerion Therapeutics stock price performed over time
Intraday
2.76%
1 week
1.56%
1 month
-2.25%
1 year
-17.41%
YTD
-18.94%
QTD
4.4%
Financial performance
How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$2M
Gross profit
$2M
Operating income
-$3.63M
Net income
-$3.06M
Gross margin
100%
Net margin
-152.9%
Cyclerion Therapeutics's net margin has soared by 94% from the previous quarter
Cyclerion Therapeutics's operating margin has soared by 94% from the previous quarter
The operating income has soared by 72% YoY and by 39% from the previous quarter
The net income rose by 42% since the previous quarter and by 42% year-on-year
Growth
What is Cyclerion Therapeutics's growth rate over time
Valuation
What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
0.8
P/S
3.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.92
Cyclerion Therapeutics's EPS has increased by 46% YoY and by 43% from the previous quarter
The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 1.8 and 13% less than its last 4 quarters average of 0.9
The equity has contracted by 22% YoY but it has grown by 8% from the previous quarter
Efficiency
How efficient is Cyclerion Therapeutics business performance
Cyclerion Therapeutics's ROS has soared by 95% from the previous quarter
The return on invested capital has surged by 89% year-on-year and by 49% since the previous quarter
The company's return on equity rose by 46% YoY and by 38% QoQ
CYCN's return on assets is up by 37% since the previous quarter and by 27% year-on-year
Dividends
What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYCN.
Financial health
How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total liabilities has plunged by 65% YoY but it has increased by 3.6% from the previous quarter
The current ratio has soared by 51% YoY and by 15% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has contracted by 22% YoY but it has grown by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.